Key result
This review summarizes clinical trials of PAH-specific therapies for adult patients with pulmonary arterial hypertension associated with congenital heart disease.
Answers are grounded in this paper and cite their sources.
This review summarizes the clinical evidence for PAH-specific therapies in adult patients with PAH associated with congenital heart disease.
PAH associated with CHD according to the Russian Register of Pulmonary Arterial Hypertension (PAH) and Chronic Thromboembolic Pulmonary Hypertension (CTEPH) is highly prevalent and ranks second after idiopathic pulmonary hypertension (IPH) in terms of prevalence among all forms of PAH and the first among associated forms. With the development of PAH, patients with congenital heart disease (CHD) require the appointment of a constant PAH-specific therapy. The article presents an overview of clinical trials of medications currently registered in the Russian Federation for this cohort of patients, including endothelin receptor antagonists (bosentan, macitentan, ambrisentan), phosphodiesterase type 5 inhibitors (sildenafil), soluble guanylate cyclase stimulants (riociguat) and prostacyclin analogues (iloprost).
No takes yet. Share an insight, caveat, or question.
Архипова et al. (2018) conducted a review in Pulmonary arterial hypertension associated with congenital heart disease. PAH-specific therapy was evaluated. This review summarizes clinical trials of PAH-specific therapies for adult patients with pulmonary arterial hypertension associated with congenital heart disease.
Synapse has enriched 10 related papers. Consider them for comparative context: